CO4700482A1 - Formulaciones de un analogo monomero de insulina - Google Patents
Formulaciones de un analogo monomero de insulinaInfo
- Publication number
- CO4700482A1 CO4700482A1 CO96015449A CO96015449A CO4700482A1 CO 4700482 A1 CO4700482 A1 CO 4700482A1 CO 96015449 A CO96015449 A CO 96015449A CO 96015449 A CO96015449 A CO 96015449A CO 4700482 A1 CO4700482 A1 CO 4700482A1
- Authority
- CO
- Colombia
- Prior art keywords
- physiologically acceptable
- insulin analog
- solution
- analog
- ppm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación farmacéutica parenteral que tiene un efectoprolongado, que consiste esencialmente en una suspensión acuosa estéril de aproximadamente 20 U/ml a aproximadamente 500 U/ml de un análogo de insulina, aproximadamente de 5 mg/ml a aproximadamente 10 mg/ml de cloruro sódico, aproximadamente 0,2 a aproximadamente 2,0 mg/ml de un tampón fisiológicamente aceptable, un contenido de iones zinc de aproximadamente 0,04 mg/ml a aproximadamente 20,0 mg/ml y un conservante fisiológicamente aceptable, a un pH de aproximadamente 6,5 a aproximadamente 7,8; tal que menos de 5% del análogo presente en la suspensión está en estado disuelto. 1Un procedimiento para preparar cristales de insulina humana-LysB28 ProB29 , que comprende combinar: una primera solución que comprende aproximadamente 300 U/ml a aproximadamente 2.000 U/ml del análogo de insulina, aproximadamente 500 ppm a aproximadamente 3.000 ppm de fenol y un exceso molar de iones zinc, a un pH de aproximadamente 2,0 a aproximadamente 3,0, y una segunda solución que comprende aproximadamente 130 mg/ml a aproximadamente 270 mg/ml de cloruro sódico y aproximadamente 5,0 a aproximadamente 55,0 mg/ml de un tampón fisiológicamente aceptable, a un pH de aproximadamente 10,5 a 12,5, de modo que el pH de la solución combinada sea de 5,0 a 6,0.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41488095A | 1995-03-31 | 1995-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4700482A1 true CO4700482A1 (es) | 1998-12-29 |
Family
ID=23643384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO96015449A CO4700482A1 (es) | 1995-03-31 | 1996-03-28 | Formulaciones de un analogo monomero de insulina |
Country Status (23)
Country | Link |
---|---|
US (1) | US5952297A (es) |
EP (1) | EP0735048A1 (es) |
JP (1) | JPH11502856A (es) |
KR (1) | KR19980703425A (es) |
CN (1) | CN1185114A (es) |
AR (1) | AR002976A1 (es) |
AU (1) | AU720300B2 (es) |
BR (1) | BR9607935A (es) |
CA (1) | CA2216516A1 (es) |
CO (1) | CO4700482A1 (es) |
CZ (1) | CZ305297A3 (es) |
EA (1) | EA000970B1 (es) |
HU (1) | HUP9801700A3 (es) |
IL (1) | IL117696A (es) |
MX (1) | MX9707428A (es) |
NO (1) | NO974498L (es) |
NZ (1) | NZ305719A (es) |
PE (1) | PE38797A1 (es) |
PL (1) | PL322626A1 (es) |
TR (1) | TR199701078T1 (es) |
WO (1) | WO1996030040A1 (es) |
YU (1) | YU18596A (es) |
ZA (1) | ZA962502B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0884053T1 (en) * | 1997-06-13 | 2003-02-28 | Eli Lilly And Company | Stable insulin formulations |
PE79099A1 (es) * | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
US20010053761A1 (en) * | 1998-01-08 | 2001-12-20 | Dimarchi Richard Dennis | Method for administering aspb28-human insulin |
WO1999048520A1 (en) * | 1998-03-24 | 1999-09-30 | Joergensen Klavs Holger | Novel preparation of protracted acting human insulin |
US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
CN1125081C (zh) | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
KR20030005204A (ko) * | 2000-12-25 | 2003-01-17 | 가부시키가이샤 시세이도 | 교감신경 활성화 향료 조성물 |
CA2431033A1 (en) * | 2001-02-09 | 2002-08-22 | Genentech, Inc. | Crystallization of igf-1 |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US7683029B2 (en) * | 2003-05-07 | 2010-03-23 | Philip Morris Usa Inc. | Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
UA91512C2 (ru) | 2004-07-19 | 2010-08-10 | Биокон Лимитед | Коньюгати олигомеров инсулина, их композиция (варианты) и применение |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
CN102026666B (zh) * | 2007-12-11 | 2013-10-16 | 常山凯捷健生物药物研发(河北)有限公司 | 促胰岛素肽缀合物制剂 |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
PL2229407T3 (pl) | 2008-01-09 | 2017-06-30 | Sanofi-Aventis Deutschland Gmbh | Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania |
ES2477552T3 (es) | 2008-09-08 | 2014-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos |
KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
KR20110082180A (ko) | 2008-10-28 | 2011-07-18 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 알데히드 탈수소효소의 조절자 및 그것의 사용방법 |
WO2010088286A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
MA33064B1 (fr) | 2009-01-28 | 2012-02-01 | Smartcells Inc | Systemes à base de conjugués pour administration contrôlée de médicaments |
WO2010092218A2 (es) | 2009-02-12 | 2010-08-19 | Proyecto De Biomedicina Cima, S.L. | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas |
AU2010226243A1 (en) | 2009-03-20 | 2011-09-22 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
EP2414560B1 (de) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Verfahren zur beschichtung einer oberfläche eines bauteils |
JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
EP3345593B1 (de) | 2009-11-13 | 2023-09-06 | Sanofi-Aventis Deutschland GmbH | Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin |
TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
JP5658268B2 (ja) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
CN102686260B (zh) | 2009-11-25 | 2014-10-01 | 贝林格尔.英格海姆国际有限公司 | 喷雾器 |
AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JP5874724B2 (ja) | 2010-06-24 | 2016-03-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
TWI608847B (zh) | 2011-08-29 | 2017-12-21 | 賽諾菲阿凡提斯德意志有限公司 | 用於控制糖尿病二型病患血糖的醫藥組合物 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
US9707276B2 (en) | 2012-12-03 | 2017-07-18 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues |
JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法 |
CN105142661B (zh) | 2013-04-03 | 2019-08-16 | 赛诺菲 | 通过长效胰岛素制剂治疗糖尿病 |
PL2835146T3 (pl) | 2013-08-09 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Nebulizator |
JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
EP3077414B1 (en) | 2013-12-04 | 2020-06-17 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
ES2954961T3 (es) | 2014-05-07 | 2023-11-27 | Boehringer Ingelheim Int | Unidad, nebulizador y método |
US10716907B2 (en) | 2014-05-07 | 2020-07-21 | Boehringer Ingelheim International Gmbh | Nebulizer |
PL3139984T3 (pl) | 2014-05-07 | 2021-11-08 | Boehringer Ingelheim International Gmbh | Nebulizator |
WO2016007682A1 (en) * | 2014-07-08 | 2016-01-14 | Amphastar Pharmaceuticals Inc. | Micronized insulin, micronized insulin analogues, and methods of manufacturing the same |
WO2016032869A1 (en) | 2014-08-26 | 2016-03-03 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin or insulin analog compositions |
PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10322168B2 (en) * | 2016-01-07 | 2019-06-18 | Amphastar Pharmaceuticals, Inc. | High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same |
EP3740212A4 (en) | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY |
EP3727424A4 (en) | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE |
BR112022019687A2 (pt) | 2020-03-31 | 2022-12-20 | Protomer Tech Inc | Conjugados para responsividade seletiva a dióis vicinais |
JP2024500284A (ja) | 2020-11-19 | 2024-01-09 | プロトマー・テクノロジーズ・インコーポレイテッド | 芳香族ホウ素含有化合物及びインスリン類似体 |
TW202409070A (zh) | 2022-05-18 | 2024-03-01 | 美商普羅托莫科技公司 | 芳族含硼化合物及相關胰島素類似物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
US2648622A (en) * | 1950-11-29 | 1953-08-11 | Research Corp | Purifying insulin by seeding with unclumped fibrils of insulin |
US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
DK78069C (da) * | 1952-06-23 | 1954-09-06 | Novo Terapeutisk Labor As | Fremgangsmåde til fremstilling af krystallinsk insulin. |
US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
US2799622A (en) * | 1953-11-14 | 1957-07-16 | Novo Terapeutisk Labor As | Process of producing insulin crystals of substantially uniform size and compositions thereof |
US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
AT304760B (de) * | 1969-08-08 | 1973-01-25 | Novo Terapeutisk Labor As | Verfahren zur Reinigung von Insulin |
DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
AU711428B2 (en) * | 1994-06-16 | 1999-10-14 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
-
1996
- 1996-03-27 AR ARP960101937A patent/AR002976A1/es not_active Application Discontinuation
- 1996-03-27 YU YU18596A patent/YU18596A/sh unknown
- 1996-03-28 CN CN96194052A patent/CN1185114A/zh active Pending
- 1996-03-28 EA EA199700285A patent/EA000970B1/ru not_active IP Right Cessation
- 1996-03-28 TR TR97/01078T patent/TR199701078T1/xx unknown
- 1996-03-28 PE PE1996000217A patent/PE38797A1/es not_active Application Discontinuation
- 1996-03-28 AU AU53812/96A patent/AU720300B2/en not_active Ceased
- 1996-03-28 HU HU9801700A patent/HUP9801700A3/hu unknown
- 1996-03-28 EP EP96302171A patent/EP0735048A1/en not_active Withdrawn
- 1996-03-28 KR KR1019970706829A patent/KR19980703425A/ko not_active Application Discontinuation
- 1996-03-28 JP JP8529728A patent/JPH11502856A/ja active Pending
- 1996-03-28 MX MX9707428A patent/MX9707428A/es unknown
- 1996-03-28 BR BR9607935A patent/BR9607935A/pt not_active Application Discontinuation
- 1996-03-28 NZ NZ305719A patent/NZ305719A/en unknown
- 1996-03-28 CA CA002216516A patent/CA2216516A1/en not_active Abandoned
- 1996-03-28 CO CO96015449A patent/CO4700482A1/es unknown
- 1996-03-28 CZ CZ973052A patent/CZ305297A3/cs unknown
- 1996-03-28 ZA ZA9602502A patent/ZA962502B/xx unknown
- 1996-03-28 IL IL11769696A patent/IL117696A/xx not_active IP Right Cessation
- 1996-03-28 WO PCT/US1996/004424 patent/WO1996030040A1/en not_active Application Discontinuation
- 1996-03-28 PL PL96322626A patent/PL322626A1/xx unknown
-
1997
- 1997-09-26 US US08/938,245 patent/US5952297A/en not_active Expired - Fee Related
- 1997-09-29 NO NO974498A patent/NO974498L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0735048A1 (en) | 1996-10-02 |
TR199701078T1 (xx) | 1998-01-21 |
NO974498D0 (no) | 1997-09-29 |
KR19980703425A (ko) | 1998-11-05 |
EA199700285A1 (ru) | 1998-02-26 |
AU5381296A (en) | 1996-10-16 |
ZA962502B (en) | 1997-09-29 |
CA2216516A1 (en) | 1996-10-03 |
NO974498L (no) | 1997-10-08 |
AU720300B2 (en) | 2000-05-25 |
EA000970B1 (ru) | 2000-08-28 |
IL117696A (en) | 2000-01-31 |
PL322626A1 (en) | 1998-02-02 |
CN1185114A (zh) | 1998-06-17 |
IL117696A0 (en) | 1996-07-23 |
BR9607935A (pt) | 1998-06-02 |
CZ305297A3 (cs) | 1998-02-18 |
MX9707428A (es) | 1997-12-31 |
HUP9801700A2 (hu) | 1998-11-30 |
JPH11502856A (ja) | 1999-03-09 |
PE38797A1 (es) | 1997-10-04 |
YU18596A (sh) | 1998-07-10 |
WO1996030040A1 (en) | 1996-10-03 |
US5952297A (en) | 1999-09-14 |
HUP9801700A3 (en) | 1998-12-28 |
NZ305719A (en) | 1998-09-24 |
AR002976A1 (es) | 1998-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4700482A1 (es) | Formulaciones de un analogo monomero de insulina | |
KR100709148B1 (ko) | 피부 노화나 손상을 치료하기 위한 아스코르브산 조성물및 방법 | |
KR970706830A (ko) | 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2'-dithio-bis (ethanesulfonate) (dimesna) | |
KR900015737A (ko) | 배합물 | |
KR900701282A (ko) | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 | |
EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
AU4185696A (en) | Increasing creatine and glycogen concentration in muscle | |
GEP19971155B (en) | Contrast medium and method for its production | |
DE69131352T2 (de) | Steigerung des glutathionspiegels durch glutamin | |
IE891118L (en) | Topical preparation for treating otopathy | |
MX9205568A (es) | Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. | |
CO5560554A2 (es) | Composicion farmaceutica que comprende lumiracoxib | |
KR880005933A (ko) | 비타민 b6-함유 약제학적 제제 | |
CA2086565A1 (en) | Pharmaceutical composition for treating pigmentation | |
US3230143A (en) | Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine | |
KR970706844A (ko) | 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor) | |
TWI263502B (en) | Pharmaceutical preparation for treating ischemic disease of heart or limbs | |
DK1019037T3 (da) | Lægemiddel indeholdende delta-aminolevulinsyre | |
GB1460325A (en) | Pharmaceutical composition intended for relieving pain and producing analgesia | |
Roth Jr et al. | The effects of nitrogen and sulfur mustards on hemoglobin S and intact red cells | |
IT1244647B (it) | Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo. | |
ES2031930T3 (es) | Un metodo para obtener una preparacion liofilizada que contiene aspoxicilina como ingrediente activo. | |
CA2120917A1 (en) | External preparation for treating hemorrhoidal diseases | |
KR900017599A (ko) | 종양 치료용 약학 조성물 | |
RU93055556A (ru) | Препарат для лечения мастита крупного рогатого скота "лизомаст" |